|Bid||0.4150 x 1800|
|Ask||0.4298 x 800|
|Day's Range||0.4200 - 0.4300|
|52 Week Range||0.4100 - 3.2600|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.22|
The clinical-stage biotech sees bottom-line improvement after slashing spending following a big pipeline setback earlier this year.
Celldex (CLDX) delivered earnings and revenue surprises of 21.43% and 2.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 11 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
HAMPTON, N.J., Aug. 08, 2018-- Celldex Therapeutics, Inc. today reported business and financial highlights for the second quarter ended June 30, 2018. The Company will host a conference call at 4:30 p.m. ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Celldex Therapeutics, Inc. (NASDAQ: CLDX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern ...
Celldex Therapeutics, Inc. (CLDX) will release second quarter 2018 financial results on Wednesday, August 8, 2018 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2018 financial results and to provide an update on key research and development and business objectives for the remainder of 2018. The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com.
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Myriad ...
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.
Stock Research Monitor: CARA, CLDX, and CORT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on CELG sign up now at www.wallstequities.com/registration . On Thursday, benchmark ...
At the start of 2017, listener Arlo added 2016’s worst-performing Rule Breaker stocks to his portfolio. Here's what happened next.
Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (CALA), Cara Therapeutics Inc. (CARA), Celgene Corp. (CELG), and Celldex Therapeutics Inc. (CLDX). Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares.
Celldex Therapeutics (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
--CDX-3379 also featured in a“ clinical trials in progress” presentation--. HAMPTON, N.J., June 02, 2018-- Celldex Therapeutics, Inc. today presented two programs at the 2018 American Society of Clinical ...
HAMPTON, N.J., June 01, 2018-- Celldex Therapeutics, Inc. announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2018 ...
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
Celldex Therapeutics Inc (NASDAQ:CLDX), a US$104.06M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
The Hampton, New Jersey-based company said it had a loss of 84 cents per share. Losses, adjusted for asset impairment costs, came to 19 cents per share. The results fell short of Wall Street expectations. ...